Poseida Therapeutics, Inc. (PSTX)
NASDAQ: PSTX · Real-Time Price · USD
2.530
+0.060 (2.43%)
Nov 4, 2024, 4:00 PM EST - Market closed
Poseida Therapeutics Employees
Poseida Therapeutics had 330 employees as of December 31, 2023. The number of employees increased by 16 or 5.10% compared to the previous year.
Employees
330
Change (1Y)
16
Growth (1Y)
5.10%
Revenue / Employee
$268,067
Profits / Employee
-$341,733
Market Cap
245.71M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
SOPHiA GENETICS | 430 |
Anika Therapeutics | 357 |
MacroGenics | 339 |
Pulmonx | 279 |
Amarin Corporation | 275 |
Editas Medicine | 265 |
Precigen | 202 |
Omeros | 198 |
PSTX News
- 11 days ago - Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema - PRNewsWire
- 18 days ago - Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche - PRNewsWire
- 4 weeks ago - Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 - PRNewsWire
- 5 weeks ago - Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement - Seeking Alpha
- 5 weeks ago - Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients - PRNewsWire
- 7 weeks ago - Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma - PRNewsWire
- 2 months ago - Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024 - Seeking Alpha
- 2 months ago - Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting - PRNewsWire